Bildkälla: Stockfoto

AroCell Q2: An unrecognized fully financed growth case - Redeye

Redeye emphasises that AroCell continues to go unnoticed by the stock market, with stable sales development, ongoing geographical expansion, and good cost control. Essentially, the Q2 financials were in line with our estimates, and we make only minor changes to our forecasts.

Redeye emphasises that AroCell continues to go unnoticed by the stock market, with stable sales development, ongoing geographical expansion, and good cost control. Essentially, the Q2 financials were in line with our estimates, and we make only minor changes to our forecasts.
Börsvärldens nyhetsbrev
ANNONSER